ARKG ETF

What Are You Actually Investing In?

By investing in ARKG, you are investing in shares of companies that develop and commercialize technologies in genomics and related fields. The ARK Invest team constructs the portfolio based on proprietary analysis, selecting companies with the highest potential.

ARKG returns are driven by: 
• changes in the market value of the companies held in the portfolio; 
• dividends paid by portfolio companies (reinvested within the fund and reflected in the share price).

Your investment is directly tied to the business performance of companies working in gene therapy, molecular diagnostics, genomic sequencing, AI-powered diagnostics, and synthetic biology.

Fund Composition

The ARKG portfolio comprises 35 companies spanning all key areas of the genomic revolution:

• Gene Editing – companies developing therapies based on CRISPR and base editing technologies for the treatment of genetic diseases. 
  CRISPR Therapeutics, Beam Therapeutics, Intellia Therapeutics
• AI in Medicine and Drug Discovery – companies applying artificial intelligence to diagnostics, medical data analysis, and accelerating the development of new treatments. 
  Tempus AI, Recursion Pharmaceuticals, Schrodinger
• Molecular Diagnostics – developers of early disease detection technologies, including liquid biopsy and genetic testing. 
  Guardant Health, Natera, Veracyte
• Synthetic Biology and Genomic Infrastructure – companies building tools and platforms for DNA synthesis, sequencing, and genomic research. 
  Twist Bioscience, Illumina, 10x Genomics, Personalis
• Gene Therapy and Biopharmaceuticals – companies developing new classes of therapies based on gene and cell technologies. 
  Adaptive Biotechnologies, Ionis Pharmaceuticals, Nurix Therapeutics

The fund's composition is reviewed by the ARK Invest team on a regular basis, ensuring the portfolio remains aligned with the latest scientific and market developments.

Fund Structure

ARKG uses a standard ETF structure: 
• company shares are held and accounted for within the fund's custodial infrastructure through licensed custodians; 
• the fund's structure is fully transparent and disclosed daily; 
• the fund operates under the oversight of US regulators and auditors.

The fund's AUM is approximately $1.25 billion. As an actively managed fund, ARKG differs from passive ETFs in that the composition and weighting of positions are determined by the ARK Invest analytical team, rather than by an index provider.

Fees and Distributions

Investor returns are driven by changes in the fund's market value. You acquire a share of ARKG at the current price and realize it upon exit – your return is determined by the change in the asset's value over the holding period.

The fund operates under the following fee structure: 
• Total Expense Ratio (TER): 0.75% per year — covering fund management, research, and administration costs. The higher TER reflects the fund's active management approach; 
• Dividends are minimal — investor returns are primarily driven by the appreciation or depreciation of the genomics companies held in the fund.

When purchasing ARKG through the Regolith platform, an entry fee of 2% of the transaction amount applies. Performance fee: 0%.

The Role of ARKG in an Investment Portfolio

ARKG is positioned as a thematic instrument for participating in the growth of genomic and biotechnology technologies. The fund can serve the following purposes:

• Participation in the genomic revolution – gene editing, AI diagnostics, and synthetic biology are at an early stage of commercialization, and the fund provides access to companies shaping these fields.
• Thematic diversification – access to 35 companies across different segments of genomics within a single instrument.
• Alternative to individual stocks – instead of placing a bet on a single biotech company, the investor gains a basket of leading players in the sector.
• Strengthening the biotech allocation – combined with broad index ETFs (such as SPY), ARKG allows targeted exposure to the healthcare and genomics sector.
• Long-term innovation play – ARK Invest considers genomics one of the five key pillars of the technological revolution over the next decade.

Current Outlook: Why ARKG Deserves Attention Now

After several years of correction, the genomics and biotechnology sector is showing signs of a turnaround. According to Seeking Alpha (February 2026), ARKG has entered an active growth phase – the fund gained over 23% in 2025, while the broader healthcare sector has demonstrated consistent positive momentum since August 2025.

Fundamental factors support this trend. The first CRISPR-based therapies have already received FDA approval – notably Casgevy by CRISPR Therapeutics (ARKG's largest holding) for the treatment of sickle cell disease and beta-thalassemia. Dozens of other CRISPR therapies are currently at various stages of clinical trials. AI-powered diagnostics are becoming the standard in oncology – Tempus AI, one of the fund's key holdings, is expanding partnerships to deploy AI platforms for early cancer detection. The cost of genome sequencing continues to decline, paving the way for the mass adoption of personalized medicine.

In its annual Big Ideas 2026 report, ARK Invest highlights multiomics – the core focus of ARKG – as one of the 13 major technology trends of the year. The firm projects a multi-fold increase in genomics sector revenue over the next decade and continues to build positions in this space.

Institutional investors are also showing interest: new positions in ARKG by hedge funds were recorded in early 2026, as reflected in 13F filings with the SEC.

For investors with a long-term horizon, the current moment may present an opportunity: the sector is at an early stage of commercializing breakthrough technologies, while valuations of many portfolio companies remain well below their 2021 peaks.

Risks

Investing in ARKG involves a number of factors typical of the biotechnology sector:

• High volatility — ARKG has a beta of approximately 1.69, meaning its price fluctuations are significantly greater than the broader market, both to the upside and downside. 
• Growth-stage companies — the majority of companies in the portfolio are in the growth and R&D phase, with many not yet achieving sustainable profitability. Their valuations are based on expectations of future results. 
• Regulatory risks — the success of portfolio companies depends on FDA and other regulatory approvals. A denial can sharply reduce a company's share price. 
• Active management risk — decisions made by the ARK Invest team regarding fund composition may prove unsuccessful, impacting returns. 
• Patent and scientific risks — companies depend on clinical trial outcomes and intellectual property protection. Failed trials or patent expirations can materially affect their value.

As an equity instrument, the fund is subject to market fluctuations and does not guarantee a positive outcome. An investor may lose part or all of their investment.

Instrument Parameters

• Ticker: ARKG 
• Type: Genomics and biotechnology ETF 
• Exchange: BATS 
• Management type: Active (ARK Invest) 
• Number of companies: 35 
• AUM: ~$1.25 billion 
• Expense Ratio: 0.75% 
• Beta: 1.69

Investor returns are driven by changes in the fund's market value.

Deposit and Withdrawal Terms via Regolith

ARKG purchases are executed on a rolling basis and are not tied to a fixed date. Transactions are processed 1–3 times per week depending on market conditions and the platform's operational schedule.

• Minimum investment period: 1 week 
• Minimum amount: $50 
• Entry fee: 2% 
• Performance fee: 0%

Withdrawals are processed according to the platform's standard procedure after the minimum investment period has been completed.